Lifetech Scientific Falls Over 14% Intraday; Company Issues 926 Million New Shares, Zylox-Tonbridge Set to Become Largest Single Shareholder

Stock News11-09

Lifetech Scientific (01302) dropped more than 14% intraday. As of press time, it was down 11.45% at HK$1.47, with turnover of HK$225 million.

On the news front, on November 6, Zylox-Tonbridge announced it had joined with Defu Capital to establish a shareholding platform to subscribe for 926 million newly issued shares of Lifetech Scientific at HK$1.60 per share, for a total of approximately HK$1.482 billion. After the transaction is completed, the platform will hold approximately 16.7% of Lifetech Scientific's enlarged share capital, becoming its largest single shareholder. Zylox-Tonbridge's management will go to Lifetech Scientific to serve as CEO and CFO.

It is worth noting that in May this year, Lifetech Scientific announced plans to acquire approximately 96.46% equity interest in Beijing Huayi Shengjie for approximately RMB 1.873 billion, with the consideration to be paid entirely in convertible bonds. The counterparty is ultimately controlled by Hillhouse Capital after look-through. If all the bonds are converted into shares, Hillhouse would hold approximately 15.66% of Lifetech's enlarged share capital and was expected to become the largest shareholder. On July 20, Lifetech Scientific announced it would no longer proceed with the transaction; on November 5, the two parties formally signed a termination agreement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment